Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 17/20 | 0.79 |
| ▸ | CCNK | O75909 | 1/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | CCND3 | P30281 | 1/20 | 0.55 |
| ▸ | CDK9 | P50750 | 1/20 | 0.55 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22166560 | 0.95 | ALK (0.70) | ALKCCNKCCNA2CDK2CCND3 | |
| SCHEMBL28427764 | 0.90 | ALK (0.67) | ALK | |
| SCHEMBL18843505 | 0.88 | ALK (1.00) | ALK | |
| SCHEMBL18843557 | 0.86 | ALK (0.77) | ALK | |
| SCHEMBL18843553 | 0.85 | ALK (0.81) | ALKEGFR | |
| SCHEMBL21844685 | 0.81 | ALK (0.76) | ALKCDK2EGFR | |
| SCHEMBL30165141 | 0.81 | ALK (0.76) | ALKCDK2EGFR | |
| SCHEMBL19027382 | 0.81 | ALK (0.80) | ALKEGFR | |
| SCHEMBL18843608 | 0.81 | ALK (0.69) | ALK | |
| SCHEMBL30180184 | 0.81 | ALK (0.80) | ALKCDK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695347-B2 | Pyrimidine derivative and use thereof | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2020-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695347-B2 | Pyrimidine derivative and use thereof | ALK, DPYD, TYMP | ALK 1/4885CCNK 108/4885CCNA2 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.